Therapy-related myelodysplastic syndrome : a retrospective analysis of data from the Czech Working MDS Group registry

Abstract

111 MDS patients were divided according to MDS subtypes (WHO classification). Time interval between exposition to mutagens and MDS development.

Chromosomal abberations were presented. Most often MDS do to therapy of brest cancer and gynecologic malignancies was found. 36% of patients transformed to AML.

Significant difference of survival according to primary malignancy, mutagenic therapy and cytogenetic abberations was not found.

Keywords

• secondary myelodysplastic syndrome
• therapy-related myelodysplastic syndrome
• sMDS